NightWare Announces Leadership Transition and Strategic Investment Plan
Minneapolis, MN – 7/25/2024
Leadership Changes
NightWare, a pioneering company dedicated to eliminating nightmare disorder for patients and supporting their caretakers and clinicians, today announced significant changes to its executive leadership and a strategic investment plan aimed at bolstering the company’s growth and market expansion.
Effective immediately, Grady Hannah has begun transitioning the role of CEO to Matthew Tucker, formerly Chief Commercial Officer and a member of NightWare’s board. Grady will transition to a key and high impact role as Chief Product Officer, focusing on advancing the NightWare platform and ensuring it meets customer needs while establishing stronger protections against competitive threats.
“Grady’s contributions to NightWare have been invaluable, and we are pleased that he will continue to play a crucial role as Chief Product Officer,” said Matthew Tucker, newly appointed CEO of NightWare. “I am honored to take on the role of CEO and look forward to leading NightWare through this exciting phase of growth and innovation, adding to our evidence, and working with customers and stakeholders to gain coverage of this game-changing and critical therapy.”
Strategic Investment Plan
NightWare remains committed to its current plan of completing its Randomized Controlled Trial (RCT) and re-engaging with key government and commercial payers to gain coverage. To significantly increase the probability of success and lay the groundwork for expansion outside government markets, NightWare plans to raise additional capital.
These investments are essential for setting the foundation for broader market expansion, which is necessary for an ultimate exit strategy that benefits all stakeholders. The company is in the process of determining the size of this capital raise and the proposed terms, which are expected to impact the structure and makeup of the board.
About Matthew Tucker
Matthew Tucker brings over 20 years of experience in MedTech commercial leadership, strategy development, and revenue growth to his new role as CEO. His career has included executive leadership positions at startups and large organizations such as Baxter Healthcare, Mylan Pharmaceuticals, and Highmark Health. His expertise ranges from P&L growth, team expansion, mergers and acquisitions, strategic planning, and market development.
“I am passionate about NightWare’s mission to eliminate nightmare disorder and support those affected by it. It’s the reason I joined this company…I wanted to ensure a game changing product was available to help as many people as it could,” said Tucker. “With the right investments and strategic direction, I am confident that we can make a significant impact and drive the company’s impact with all stakeholders to new heights.”
About NightWare
NightWare is dedicated to eliminating nightmare disorder for patients and assisting the caretakers and clinicians who treat it. The company’s innovative platform has shown promise in providing relief to those suffering from this condition, and NightWare continues to work towards expanding its reach and impact.
For more information about NightWare and its mission, please visit NightWare’s website https://www.nightware.com.